Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Ethics Forum: Ethics of Infusions in the Face of A Professional Conflict

Leyka M. Barbosa, MD  |  Issue: August 2013  |  

Dr. Barbosa is director of North Texas Joint Care, PA, in Dallas.

References

  1. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806.
  2. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: Results of a systematic literature search. Ann Rheum Dis. 2010;69:638-643.
  3. Texas Administrative Code. Title 22: Examining Boards, Part 9: Texas Medical Board, Chapter 165: Medical Records, Rule §165.2, Medical Record Release and Charges.

Related Articles

    Higher Risk of Adverse Events When Biologic Infusions Are Done at Home

    (Reuters Health)—Patients who receive biologic infusions at home may have a higher risk of adverse events than those who receive the infusions at a health care facility, a new study suggests.1 Researchers examined administrative claims data on 57,220 adults who received a total of 752,150 biologic infusions for immune-mediated disease between 2007 and 2017. The…

    Ethics Forum: Patient Safety at Home—What Are Our Legal & Ethical Responsibilities?

    A 60-year-old woman with a six-month history of retroperitoneal fibrosis transfers her care to you. She initially presented with severe bilateral flank pain radiating to the abdomen and chest. A computerized tomography (CT) angiogram of the abdomen demonstrated an infrarenal abdominal aortic aneurysm surrounded by a thick inflammatory rind entangling the left renal vein and…

    Rituximab Maintenance Study: Is Fixed-Schedule or Tailored Dosing Best?

    Rheumatologists prescribe rituximab for induction and maintenance treatment for anti-neutrophil cytoplasm antibody (ANCA) associated vasculitides (AAV). Maintenance treatment typically employs fixed-schedule dosing, but in the recent maintenance of remission using rituximab in systemic ANCA-associated vasculitis II (MAINRITSAN2) trial, researchers from the French Vasculitis Study Group examined whether individually tailored maintenance dosing might work better. “The…